Intra-abdominal infections (IAIs) remain a major clinical challenge, requiring precise management strategies. Over the years, guidelines from the Surgical Infection Society (SIS) have provided clinicians with evidence-based strategies to improve patient outcomes. The 2024 update of the SIS guideline on the Management of Intra-Abdominal Infection focuses on refining existing recommendations and providing new insights.  

For further exploration of these updated guidelines, including detailed recommendations and methodologies, you can access the full SIS 2017 and 2024 guidelines and compare them through the following links.

Here are a few of the differences from the 2017 version and what remains consistent.

Key Changes in 2024
  • Adult-Only Focus
    Unlike the 2017 guidelines, which covered both adults and pediatric patients, the 2024 update is exclusively for adults. A separate guideline for pediatric IAIs is coming. This change allows for more precise recommendations tailored to the adult population.
  • Higher-Quality Evidence
    The 2024 guidelines restrict evidence sources to randomized controlled trials (RCTs), systematic reviews, and meta-analyses, improving the quality and consistency of recommendations. The 2017 guidelines relied on a broader spectrum of evidence, including retrospective studies and other observational data.
  • Broad-Based Literature Search
    Instead of focusing on pre-formed clinical questions, the writing group conducted a comprehensive literature search across multiple databases. This ensures a more expansive understanding of the latest research, while the 2017 guidelines revolved around specific pre-set questions.
  • Supplementary Nature
    The 2024 update aims to supplement, not replace, previous guidelines. It refines earlier recommendations without rendering them outdated. The 2017 version was designed as a comprehensive revision.
Key Similarities
  • Grading System (GRADE)
    Both the 2024 and 2017 guidelines use the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) system. This system rates the strength of each recommendation as strong (1) or weak (2), and the quality of evidence as high (A), moderate (B), or weak (C), ensuring clarity in clinical decision-making​.
  • Risk Stratification
    Both guidelines highlight the importance of stratifying patients based on illness severity, microbiological risk, and the potential presence of multidrug-resistant (MDR) organisms. This ensures that treatment plans are tailored to individual patient needs, reflecting personalized care.
  • Source Control as a Cornerstone
    As with the 2017 guidelines, the 2024 update reinforces the critical role of timely source control in treating IAIs. The update builds on this concept by incorporating newer insights into the timing and approach to these procedures.

The 2024 SIS guidelines reflect both an evolution and a continuation of earlier work. By focusing on high-quality evidence and tailoring recommendations specifically for adult patients, the guidelines provide a more robust and reliable framework for managing IAIs. At the same time, they retain essential components from 2017, such as the use of the GRADE system and the emphasis on risk stratification and source control. As healthcare continues to evolve, these guidelines will undoubtedly serve as a critical resource for clinicians managing this challenging condition.

Sign up for alerts and stay informed on the latest published guidelines and future installments of our Guidelines Timelines.

Copyright © 2024 Guideline Central, All Rights Reserved.